Results 151 to 160 of about 32,832 (202)

Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review). [PDF]

Int J Oncol
Du J, Shen H, Zeng T, Liu W, Xie Y.
europepmc   +1 more source

Tumor Anti-Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment. [PDF]

Cancer Med
Tang Y, Ding Y, Wang L, Yang Y, Han Y, Zhou P, Qu H, Deng K, Xia J.   +8 more
europepmc   +1 more source

Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. [PDF]

Onco Targets Ther
Zhang K, Ren Y.
europepmc   +1 more source

Proteome-Wide Analysis of Functional Phosphosites in the FGFR Family of Proteins: Insights from Large-Scale Phosphoproteomic Analysis. [PDF]

Proteomes
Palollathil A, Mahin A, Perunelly Gopalakrishnan A, Poojari TR, Sambreena A, Basthikoppa Shivamurthy P, Raju R.   +6 more
europepmc   +1 more source

Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective. [PDF]

J Mammary Gland Biol Neoplasia
Tuokkola JE, Schwertfeger KL.
europepmc   +1 more source

Reflex somatic testing for the detection of FGFR alterations in urinary tract carcinomas: A dual-institutional experience. [PDF]

Am J Clin Pathol
Nguyen NJ, Olkhov-Mitsel E, Craddock KJ, Flood TA, Downes MR.   +4 more
europepmc   +1 more source

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in <i>FGFR2</i>-amplified gastric cancer. [PDF]

Elife
Zhang Y, Wang H, Wei Y, Pan Y, Song X, Shao J, Yu L, Shi T, Wang Y.   +8 more
europepmc   +1 more source

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. [PDF]

J Clin Invest
Werr L, Boland J, Petersen J, Iglesias F, Höppner S, Bartenhagen C, Rosswog C, Hellmann AM, Kahlert Y, Hemstedt N, Ibruli N, Dammert MA, Decarolis B, Werner JM, Malchers F, Schramm K, Witt O, Beiske KH, Rognlien AGW, Gunnes MW, Langenberg KP, Molenaar J, Bernkopf M, Taschner-Mandl S, Hughes D, George SL, Chesler L, Schulte JH, Barone G, Capasso M, Surrey LF, Bagatell R, Masliah-Planchon J, Schleiermacher G, Grüll H, Westermann F, Schultheis AM, Büttner R, Henssen AG, Eggert A, Peifer M, Shukla NN, Simon T, Hero B, Reinhardt HC, Thomas RK, Fischer M.   +46 more
europepmc   +1 more source

Targeting the FGF19/FGFR4 positive feedback loop to disrupt ERK-mediated tumor progression in head and neck cancer. [PDF]

J Transl Med
Yang YF, Yu PL, Chou CY, Lin YH.
europepmc   +1 more source

Molecular Analysis of EBUS-TBNA Samples for Nodal Staging in Non-Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Ehab A, Benabdallah N, Darwiche K.
europepmc   +1 more source